Background {#Sec1}
==========

Cognitive impairment late in life is commonly caused by progressive neuronal loss related to two dominant diseases, Alzheimer's disease (AD) and small vessel cerebrovascular disease (i.e. vascular dementia; VaD), both causing brain atrophy years before clinical symptoms are detected. As dementia is attributed to vascular and life-style related risk factors in mid-life in a substantial proportion of patients (50%), there is an opportunity to modify these factors if incipient disease is detected earlier \[[@CR1]\]. Transient ischemic attack (TIA; incidence 0.37--1.1 per 1000) \[[@CR2], [@CR3]\], is associated with a 4-fold increase in dementia over the general population \[[@CR4]--[@CR6]\]. Therefore, TIA patients are a potential target for early modification of incipient disease processes that precede cognitive impairment guided by biologically relevant markers such as amyloid beta 1--42/ tau, whole brain and sub-structure atrophy, small vessel disease markers, and increased free iron. The Predementia Neuroimaging of Transient Ischemic Attack (PREVENT) study will focus on quantifying these biomarkers using advanced serial magnetic resonance imaging (MRI), neuropsychological assessments, APOE genotyping, and longitudinal clinical data. Specifically, PREVENT will examine what combination of pathological processes and risk factors lead to cognitive decline after TIA.

Methods {#Sec2}
=======

PREVENT is a prospective, single-center longitudinal study. To achieve a 30% group effect size on annualized rates of cerebral brain atrophy, *N* = 220 TIA patients and *N* = 220 healthy controls will receive clinical, neuropsychological, fluid biomarker, and MR assessments at pre-specified time points. The frequency and duration of events is summarized in Table [1](#Tab1){ref-type="table"}.Table 1Schedule of EventsVisit NameBaselineMonth 12Year 3Annual ReviewInterim ReviewInclusion and Exclusion Criteria•Medical History, Physical Exam••••Vital (BP, Heart rate etc.,) Signs••••DNA Sample Collection for APOE•Neuropsychological assessment•••Activities of Daily Living (FAQ)•••Plasma and Serum Biomarker Collection••••Concomitant Medications•••••Adverse Events•••••3 T MRI Imaging (100%)•••CSF Collection by Lumbar Puncture•

Patient and control subject populations {#Sec3}
---------------------------------------

The inclusion criteria for the TIA patient cohort are: 1) First documented TIA as defined by the following: resolved symptoms attributable to the anterior circulation (motor, speech, monocular visual loss), or posterior circulation (two or more of: ataxia, diplopia, vertigo, hemi-weakness, hemianopia) \[[@CR2]\]; 2) no dementia as defined by National Institute of Aging-Alzheimer Association Criteria \[[@CR7]\]; 3) clinical brain MR within 10 days of TIA symptoms to determine presence of diffusion-weighted image (DWI) lesion; 4) an age range between 45 and 75 years; and 5) fluency in English language.

Patient exclusion criteria are as follows: 1) persistence of stroke symptoms \> 24 h \[[@CR2]\]; 2) dementia as defined by the National Institute of Aging-Alzheimer Association Criteria \[[@CR7]\]; 3) other central nervous system disease (e.g. MS), alcoholism, substance abuse, sedatives, antipsychotic medications and history of psychiatric illness; 4) contraindication to MR imaging, and other comorbidities that could significantly interfere with cognitive performance and follow-up (e.g., recent coronary artery bypass surgery (within 6 months), severe ischemic heart disease, heart failure, poorly controlled diabetes, renal or liver failure etc.).

Healthy controls will include volunteers from the community, and spouses of patients. Exclusion to participation includes prior stroke or TIA, dementia, co-morbid disease etc. as per patient exclusion criteria.

Data collection {#Sec4}
---------------

Baseline evaluation (time point: Year 0; Y0) will include clinical review, fasting cholesterol, glucose, and renal function tests. Treatments for hypertension, diabetes, hyperlipidemia, anti-thrombotic agents, and other medications that could influence cognition such as sedatives, anxiolytics, or psychotropic medications will be determined. Apolipoprotein E (APOE) genotyping will be performed; the APOE ε4 allele is a risk factor for AD and VaD \[[@CR8]\]. Obstructive sleep apnea may affect cognition and will be screened \[[@CR9]\]. Blood pressure (BP) measurement will include two sitting BP measurements taken 5 minutes apart. At enrollment, patients and healthy controls will have home BP monitoring training and will perform three readings per day (waking, mid-morning, and evening) with a Bluetooth enabled, telemetric system (A&D Model UA 767BT) during the first month of recruitment \[[@CR10]\]. All TIA patients will be managed according to current stroke prevention guidelines \[[@CR11]\]. Cerebrospinal fluid (CSF) for AD biomarkers, amyloid β~1--42~ and tau, will be collected according to a standardized procedure \[[@CR12], [@CR13]\]. The PREVENT study consent informs the participant that all results from biological tests (i.e. APOE) will not be disclosed to the patient or to the patient's general practitioner. Participants will be approached about brain donation.

Imaging acquisition {#Sec5}
-------------------

At study entry **(**Y0**)** patients will have MR scan as a standard of clinical care within 1--2 days of physician assessment, and then repeated at 1 (Y1) and 3 years (Y3). Healthy controls will have MR scan at the same time points (Y0, Y1, Y3). DWI will be performed to detect evidence of diffusion lesion after TIA (up to 30%) \[[@CR14]\]. The pertinent biological imaging targets of the standard MR imaging acquisition are summarized in Table [2](#Tab2){ref-type="table"}. The absolute brain and hippocampal volume change between Y0, Y1, and Y3 will be calculated from T1-weighted images with SIENA \[[@CR15]\] and FIRST \[[@CR16], [@CR17]\] part of FSL software package \[[@CR18], [@CR19]\]. At baseline and follow up, FLAIR images will be registered to high-resolution T1 images using a rigid transformation and optimization of the mutual information. Quantitative Susceptibility Mapping (QSM) measurements of regional brain iron accumulation will be acquired using methodology developed and published by the Calgary Image Processing and Analysis Center (CIPAC) \[[@CR20]\].Table 2PREVENT imaging comprehensive dementia protocol \< 20 min of scan timeImaging SequenceMechanistic TargetEndpointGeometric Parameters (2D/3D, FOV)Acquisition Parameters (TE/TR/flip)3-plane localizer2D, 24 cm, 8 mm/ 8 mm, 33, 256 × 1281.3 ms/ 4.8 ms/ 30°High Resolution T1-weightedAtrophyPrimary and secondary outcome3D, 24 cm^2^ 2.0 mm/ 0 mm, 70, 256 × 2563 ms/ 7 ms/ 8° (minTE, minTR)3D T2-weighted FLAIRWML volumePredictor of primary outcome3D, 24 cm, 1 mm/ 0 mm, 38, 256 × 256140 ms/ 9000 ms/ 90°Axial 3D QSMNeurodegeneration Brain iron contentPredictor of primary outcome3D, 24 cm, 2 mm/0 mm, 192 × 19229.5 ms/3 ms/8°3D Proton DensityWML volume3D SPGR, 1 mm/ 0 mm, 256 × 256Diffusion tensor DWIMicrostructure Acute cytotoxic ischemia2D, 24 cm, 3.5 mm/ 0 mm, 38, 144 × 144 matrix70 ms - 80 ms/ 13,000 ms/ 90°Axial T2 starMicrohemorrhage2D, 24 cm, 3.5 mm/ 0 mm, 38, 256 × 224140 ms/ 9000 ms/ 90°7

Neuropsychological assessment {#Sec6}
-----------------------------

Performed at baseline (within 10 days of onset in TIA patient) and then annually by a trained research assistant (Table [3](#Tab3){ref-type="table"}). The cognitive tests are designed to measure change over time, have been selected to minimize floor and ceiling effects, can distinguish normal aging from prodromal dementia, and will be rotated to reduce practice effects. These tests are consistent with harmonization standards for vascular cognitive impairment (VCI) \[[@CR21]\].Table 3PREVENT Neuropsychological BatteryDomainTestDescriptionAttentionTrail Making A \[[@CR52]\]Measure of attention, speed and mental flexibility through connecting numbers from 1 to 25 in ascending order.Processing SpeedDigit Symbol Coding Test (WAIS-IV) \[[@CR53]\]Assessment consisting of 9 digit-symbol pairs followed by a list of digits. Subject instructed to fill in the corresponding symbol within 120 s.Verbal MemoryWHO/UCLA's Auditory Verbal Learning Test \[[@CR54]\]Measure of verbal learning and memory. Subject asked to repeat a list of words (List A) for 5 consecutive trials. An interference trial is introduced (List B) followed by immediate recall and a 25-min delayed recall.Visual MemoryBrief Visuospatial Memory Test -- Revised (BVMT) \[[@CR55]\]Measure of visual learning and memory. Target figures presented to subject for 10 s for 3 consecutive drawing trials. After a 25-min delay subject is asked to redraw target figures. Recognition trial is almost administered using 6 novel and 6 target figures.Executive FunctionStroop Color Word Test \[[@CR56]\]Measure of executive function to assess cognitive control. Subjects instructed to read colors out loud while ignoring the printed words in 45-s.Trail Making B \[[@CR52]\]Measure of mental flexibility. Subject asked to connect alternating numbers (1--13) and letters (A-L).Clox-1: Executive Clock Drawing \[[@CR57]\]Measure of visual spatial construction and executive abilities; also screens for dementia. The subject is instructed to draw a clock with hands and numbers and a specific time.Working MemoryDigit Span Forward \[[@CR58]\]Test of working memory. Subject is asked to repeat back a list of numbers verbatim as they increase in difficulty.Digit Span Backwards \[[@CR58]\]Test of working memory. Subject is asked to repeat the list of words in backwards order as they increase in difficulty.LanguageBoston Naming Test (Short form) \[[@CR59]\]Assessment of visual naming ability. Subject is asked to name 15 objects after being presented with an illustration.Complex Ideation Material \[[@CR60]\]Assessment of error detection that may be attributed to dementia. Subject is asked yes/no questions about areas that are considered general knowledge. Subject is then read two stories and asked yes/no questions post-comprehension.Premorbid IntelligenceNorth American Adult Reading Test (NAART) \[[@CR61]\]Measure of premorbid intelligence. The subject is asked to read a list of 61 words out loud.MoodCenter for Epidemiological Studies - Depression Scale (CES-D) \[[@CR62]\]Self-reported questionnaire. The subject is asked to fill out a questionnaire that pertains to their mood and well-being.Cognitive Screening TestsMontreal Cognitive Assessment (MoCA) \[[@CR63]\]Assessment of multiple cognitive domains; sensitive to mild cognitive impairment and dementia.Addenbrooke's Cognitive Assessment -- Revised (ACE-R) \[[@CR64]\]Assessment of multiple cognitive domains; sensitive to MCI and dementia. The test has a built in mini mental state examination (MMSE).

Power analyses {#Sec7}
--------------

The PREVENT study will recruit 220 TIA patients to participate in this study and compare them to 220 controls, which is inclusive of 20% attrition rate in the whole sample, informed by our preliminary data and by other well documented longitudinal studies \[[@CR22]--[@CR24]\]. The study is powered based on multiple linear regressions of the association between the primary outcome of interest, first year cerebral atrophy rate (R1), and group effect, after adjusting for other socio-demographic, clinical, and vascular risk factors, and other potential confounders. With a sample size of 440, the study will have at least 85% power to detect a 30% group effect size (i.e. TIA versus control) following baseline measurement and follow up measurement taken at Y1, informed by similar rates of whole brain atrophy in published reports of prodromal dementia \[[@CR25], [@CR26]\], and our pilot data \[[@CR27], [@CR28]\]. This sample size will provide at least 90% power to detect a standardized difference of 0.35 between TIA and control groups for change over time on the WHO/UCLA AVLT (verbal memory) and Trails A and B tests (processing speed/executive function).

Statistical analyses {#Sec8}
--------------------

Statistical analysis will include descriptive statistics to compare the mean, median, standard deviations, and frequency distribution s of all variables.

A mixed repeated measure regression model will be used to model the association between overall cognitive domain specific and composite z-score variable measures at baseline, 1 year, and 3 years and patient group (TIA versus healthy control), after adjusting for demographic characteristics, baseline cognitive function, vascular risk factors mentioned before, in vivo biomarkers, and patient interactions as fixed effects covariates. The size of the standardized regression coefficients associated with each predictor will be used to quantify its relative importance in predicting rate of cognitive decline in patients versus controls. A random intercept will be included to account for subject-specific variation in cognitive scores. The 95% confidence intervals and the corresponding *p*-values for adjusted group effect on overall cognitive outcomes will be estimated.

Finally, we will develop novel prediction models based on machine learning and generalized estimating equation models to identify individual TIA patients with a high likelihood to develop cognitive decline. The basic idea of this is to predict occurrence of cognitive decline using prediction models developed and trained on the longitudinal data with known clinical outcome (cognitive decline yes / no), which can then be used to predict cognitive impairment in new patients based on the same features used for training of the high-level machine learning model. More precisely, we will develop prediction models based on random forest \[[@CR29]\], support vector machines \[[@CR30]\], deep neural networks \[[@CR31]\], and quadratic inference function classifiers for predicting the occurrence of dementia using available baseline information such as cognitive test results, blood and CSF parameters, as well as quantitative image-based biomarkers such as regional QSM values, volumetric brain and hippocampal values, and white matter lesion (WML) load. The evaluation of the prediction models based on the TIA and control cohorts will be conducted using well-established cross validation techniques. This means that we will, for example, exclude one patient with known dementia outcome from the training set. After this, the prediction model trained based on the remaining patients can be used to predict dementia outcome for the one patient not part of the training set and the predicted outcome can be compared to the real outcome. By iteratively repeating this so-called leave-one-out cross validation for all patients available, the accuracy of the prediction model can be determined and used to identify the optimal high-level machine learning method for this purpose.

Discussion {#Sec9}
==========

In light of social and economic burdens, early identification of high-risk patients for dementia is the most important step in prevention and postponement \[[@CR32], [@CR33]\]. With no cure and recent clinical trial failures, it is becoming increasingly important that trials must be redesigned with a focus on high-risk populations and standardized biomarkers, which include clinical, demographic, imaging and neuropsychological considerations. The PREVENT study proposes the early identification of people at risk for late-life cognitive decline as the single most important approach for trial designs. To date, studies have established a link between vascular risk and stroke, and late life cognitive impairment but overlooked fundamental challenges such as the efficacy of vascular reduction treatment (antihypertensive treatments \[[@CR34]--[@CR38]\], diabetes management, and cholesterol lowering therapy \[[@CR39]\]) on slowing cognitive decline, thus leading to inconclusive results. Special consideration needs to be given to identifying patients at the highest risk of dementia (i.e. TIA patients) since these patients are most likely to benefit from earlier intervention \[[@CR40]\] before symptoms manifest, and from therapies that focus on vascular risk reduction \[[@CR34]\]. Intervention trials such as the Finnish Geriatric Interventions to Prevent Cognitive Impairment (FINGER) study and the Prevention of Dementia by Intensive Vascular care (preDIVA) trial, show that focusing on diet, exercise, cognitive training, and vascular risk management as a multi-domain treatment approach improves or maintains cognitive function in at risk elderly when compared to healthy controls \[[@CR24], [@CR41]\]. The potential mechanisms of disease progression (AD, vascular disease or both), response of these multi-domain therapeutic interventions, and their long-term benefits remain unknown \[[@CR42]\]. However, epidemiological studies show that the incidence or age specific prevalence of dementia has declined in the past 20 years \[[@CR43]--[@CR45]\], implying that the risk of dementia is modifiable through vascular risk reduction therapies. The early identification of patients at greatest risk of cognitive decline, by measuring change in cognition, is an important issue to be addressed by the PREVENT study.

The PREVENT study is expected to support the concept that rate of cerebral atrophy is a meaningful measure of disease progression that precedes cognitive decline and provide justification for the use of rates of cerebral atrophy as an outcome in pre-clinical dementia prevention trials. The PREVENT study in its design will stratify dementia risk according to biological markers of neurodegeneration, and small vessel cerebrovascular disease. We anticipate that the PREVENT study will demonstrate the temporal order of biomarker (in vivo AD and small vessel disease features) change as shown in the figure below with more advanced decline of brain volume occurring in order as follows: Alzheimer's pathology plus cerebrovascular disease, Alzheimer's disease in isolation, small vessel cerebrovascular disease and low vascular risk group without identifiable in vivo markers of either vascular disease or AD, all starting before clinical symptoms manifest (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PREVENT stratification of dementia risk by biomarker profile for future dementia prevention clinical trials

We anticipate that recruitment will be the most important challenge to the feasibility of the PREVENT Study. Clinical evaluations, cognitive tests, and the MRI protocol have been designed to minimize patient fatigue, and will be only performed yearly (inclusive of year 5). Recruitment is ahead of schedule providing powerful evidence that enrollment of TIA patients and healthy controls will be complete by the end of 2018. We are actively recruiting from a repository of healthy community volunteers (Calgary Normative Study). We anticipate that by the end of 2019 we will have completed our primary outcome measure of early rates of brain atrophy (R1). By 2021, secondary outcome measures of rates of brain atrophy will have been completed 3 years (R2) and biomarkers of Alzheimer's disease in WML will have been analyzed. All patients will have completed 4 years of serial neuropsychological assessments.

Our sample size calculations for the PREVENT study are inclusive of an estimated attrition rate of 20%, which is similar to drop out rates in other longitudinal studies of cerebrovascular disease and cognition \[[@CR46]\]. Potential bias of our results through the withdrawal or death of subjects at highest risk of dementia will be mitigated by the age inclusion criteria (45--75). Moreover, unlike stroke patients, TIA patients will be able to physically and cognitively comply with serial cognitive and MR imaging. All study participants will be under regular surveillance during clinical reassessments for the development of cardiovascular events and death. Confirmed cases of recurrent stroke will be excluded from our primary outcome analysis; recurrence is anticipated to be low (\< 2%) \[[@CR47]\].

A proportion of PREVENT subjects may have diffusion-weighted lesions (possibly up to 30%) \[[@CR14]\], but previous studies have shown that presence of such small silent infarcts may not explain the cognitive profile \[[@CR48]\], nor the progressive cognitive decline \[[@CR49]\], perhaps implicating neurodegenerative and inflammatory processes \[[@CR50], [@CR51]\]. The presence of DWI lesions may be another predictor of progressive brain atrophy. Exploring disease mechanisms implicated in the recently reported interactions between incident stroke and persistent progressive cognitive decline will be important to furthering our understanding of the disease interaction of neurodegenerative and cerebrovascular processes on cognitive decline \[[@CR49]\].

We have set rigorous standards for maintaining the highest quality MR images, including the application of similar benchmark standards used by the Alzheimer's Disease Neuroimaging group ([adni.loni.usc.edu](http://adni.loni.usc.edu)). Objective quality assurance to detect image distortion will be diligently followed to measure properties that include grading calibration, image contrast, and signal to noise ratio. Any scans that fail quality control will be repeated within 4 weeks.

The PREVENT study will be the first critical step for identifying individuals at increased risk of late life cognitive decline. Future steps will target individuals at the highest risk of dementia before symptoms develop, thereby identifying an enriched disease group to test preventative and disease modifying strategies in clinical trials that aim to reduce the microscopic brain tissue loss over a relatively short period of time, thereby optimizing the opportunity for preventing dementia in the future.
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